MaGOmega®
Solutex has developed a full range of ingredients under the brand MaGOmega® featuring Omega-3 in monoglyceride (MAG) form for greater bioavailability.
Solutex is the only supplier providing a vegan option in MAG form.
Greater bioavailability
Monoglycerides have shown greater bioavailability in the body than triglycerides and ethyl esters, as demonstrated in several studies.
Omega-3 in MAG form has higher oral bioavailability compared to TG or EE forms:
Figure 1: Plasma EPA concentrations in healthy adults, in the 24h after taking MAG, EE and TG omega-3 FA supplementations. (Modified from J Nutr 2021;00:1–8.).
J Nutr 2021;00:1–8. doi:10.1093/jn/nxaa458
Digestion Process of Omega-3 Fatty Acids
The most commonly commercialized forms of omega-3s are ethyl ester (EE) and reconstituted triglycerides (TG). Studies evaluating the pharmacokinetics of omega-3 fatty acids esterified in different forms reported that the most bioavailable form is when provided in MAG > TG > EE.
EE and TG forms need to be broken down into smaller components by lipases in the digestion process for absorption in the mucosal cells of the digestive tract, whereas monoacylglycerol (MAG) forms, as well as Free Fatty Acids (FFA), are considered as being in a predigested form, ready to be absorbed:
Highly efficient in lower dosages
- MaGOmega® delivery form provides greater absorption and oral bioavailability of Omega-3 allowing lower doses to achieve Omega-3 health benefits.
- MaGOmega® is also a great solution for those who suffer from digestive issues and impaired lipid absorption due to health challenges.
Benefits
- Unique and IP protected
- More readily bioavailable
- Highest concentrations available
- Non-GMO
- Shelf-life: 24 months
- No environmental contaminants
-
Algae
- Vegan DHA Monoglyceride
- Up to 60% DHA
- Exclusive formula suitable for vegan diet
- Schizochytriumn sp – microalgae – sourced from Europe
- Generally Recognized as Safe (GRAS)
MaGOmega Algae sourced
- MaGOmega®0060 Algae
MaGOmega® Results
MaGOmega® was tested in a pilot study conducted in cystic fibrosis (CF) patients, a health condition that leads to fat malabsorption and malnutrition, and demonstrated that the medical food MAG-DHA (MaGOmega) represents a solution to overcome the impaired absorption of DHA in CF patients:
Results showed a ~2-fold increase of the DHA levels after 1 month of MaGOmega® supplementation while a previous clinical study on CF patients using a triglyceride form showed a 1.6-fold increase and after 3 months of supplementation.
Mar. Drugs 2018, 16, 184; doi:10.3390/md16060184
| Europe | |
|---|---|
| Global Headquarters Av. de la Transición Española 24, Edificio Gamma 28108 Alcobendas Madrid, Spain P: +34 918.060.477 F: +34 918.060.605 |
Manufacturing Site Polígono Industrial El Zafranar Calle Rioja 6, 50550 Mallén Zaragoza, Spain P: +34 976.866.314 F: +34 976.850.123 |
| North America | Central Asia |
|---|---|
| Commercial Office One Technology Place 200 East First St., Suite 104 Winston-Salem, N.C. USA 27101 P: +1 336.306.8536 |
Commercial Office The Landmark Building Sector 7 Office 1010-Plot 26-A Kharghar, Navi Mumbai 410210 Maharashtra, India P: +91 222.087.0349 |
